Hims & Hers Health, Inc. (NYSE:HIMS) Given Average Rating of “Moderate Buy” by Brokerages

Shares of Hims & Hers Health, Inc. (NYSE:HIMS) have received an average rating of “Moderate Buy” from the sixteen analysts that are currently covering the firm, Marketbeat reports. Seven research analysts have rated the stock with a hold recommendation and nine have issued a buy recommendation on the company. The average twelve-month target price among brokers that have covered the stock in the last year is $17.00.

Several research firms have commented on HIMS. Deutsche Bank Aktiengesellschaft upped their target price on shares of Hims & Hers Health from $14.00 to $16.00 and gave the stock a “hold” rating in a research report on Tuesday, May 7th. Bank of America lifted their target price on Hims & Hers Health from $22.00 to $26.00 and gave the company a “buy” rating in a research note on Thursday, June 13th. Canaccord Genuity Group assumed coverage on Hims & Hers Health in a report on Wednesday, April 10th. They issued a “buy” rating and a $20.00 target price for the company. TheStreet raised shares of Hims & Hers Health from a “d” rating to a “c” rating in a research report on Monday, March 4th. Finally, Seaport Res Ptn reaffirmed a “buy” rating on shares of Hims & Hers Health in a report on Friday, April 26th.

Hims & Hers Health Stock Up 0.8 %

Shares of HIMS stock opened at $20.19 on Monday. The company has a market cap of $4.34 billion, a P/E ratio of -2,019.00 and a beta of 1.08. The business has a 50 day moving average of $17.59 and a two-hundred day moving average of $13.55. Hims & Hers Health has a 52 week low of $5.65 and a 52 week high of $25.74.

Hims & Hers Health (NYSE:HIMS) last released its quarterly earnings data on Monday, May 6th. The company reported $0.05 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.02 by $0.03. The business had revenue of $278.20 million during the quarter, compared to analyst estimates of $270.37 million. Hims & Hers Health had a negative return on equity of 0.70% and a negative net margin of 0.24%. The business’s revenue for the quarter was up 45.8% compared to the same quarter last year. During the same quarter in the previous year, the firm posted ($0.05) EPS. Analysts expect that Hims & Hers Health will post 0.2 EPS for the current fiscal year.

Insider Transactions at Hims & Hers Health

In related news, insider Soleil Boughton sold 2,502 shares of the company’s stock in a transaction on Tuesday, May 28th. The stock was sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the transaction, the insider now directly owns 156,855 shares in the company, valued at $2,718,297.15. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through the SEC website. In related news, insider Soleil Boughton sold 2,502 shares of the stock in a transaction dated Tuesday, May 28th. The shares were sold at an average price of $17.33, for a total value of $43,359.66. Following the completion of the transaction, the insider now owns 156,855 shares of the company’s stock, valued at $2,718,297.15. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is accessible through the SEC website. Also, Director Christiane Pendarvis sold 4,000 shares of Hims & Hers Health stock in a transaction that occurred on Monday, May 13th. The shares were sold at an average price of $12.33, for a total value of $49,320.00. Following the sale, the director now directly owns 11,210 shares in the company, valued at $138,219.30. The disclosure for this sale can be found here. In the last quarter, insiders have sold 960,288 shares of company stock valued at $16,891,553. 17.71% of the stock is owned by corporate insiders.

Institutional Investors Weigh In On Hims & Hers Health

Several institutional investors and hedge funds have recently made changes to their positions in HIMS. Victory Capital Management Inc. lifted its holdings in Hims & Hers Health by 23.0% during the 4th quarter. Victory Capital Management Inc. now owns 18,348 shares of the company’s stock valued at $163,000 after purchasing an additional 3,429 shares during the last quarter. Graham Capital Management L.P. boosted its holdings in shares of Hims & Hers Health by 39.4% in the 3rd quarter. Graham Capital Management L.P. now owns 340,338 shares of the company’s stock worth $2,141,000 after acquiring an additional 96,277 shares in the last quarter. Forerunner Ventures Management LLC bought a new stake in Hims & Hers Health during the 4th quarter worth approximately $86,836,000. Swiss National Bank increased its holdings in Hims & Hers Health by 9.2% during the 3rd quarter. Swiss National Bank now owns 309,200 shares of the company’s stock valued at $1,945,000 after purchasing an additional 26,100 shares in the last quarter. Finally, Vanguard Group Inc. raised its position in Hims & Hers Health by 3.1% in the 3rd quarter. Vanguard Group Inc. now owns 14,126,744 shares of the company’s stock valued at $88,857,000 after purchasing an additional 428,671 shares during the last quarter. Institutional investors and hedge funds own 63.52% of the company’s stock.

Hims & Hers Health Company Profile

Hims & Hers Health, Inc operates a telehealth platform that connects consumers to licensed healthcare professionals in the United States, the United Kingdom, and internationally. The company offers a range of curated prescription and non-prescription health and wellness products and services available to purchase on its websites and mobile application directly by customers.